Analyst consensus rating
Mineralys Therapeutics Analyst Rating: none
MLYS is rated none by 8 analysts with a $48.50 target. As of 2026-08-31.
Direct answer
Mineralys Therapeutics's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $48.50.
Forecast evidence checked August 31, 2026.
Get free Mineralys Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $25.67
- Average price target
- $48.50
- High price target
- $56.00
- Low price target
- $30.00
- Low target gap
- +16.9%
- Target upside
- +88.9%
- High target gap
- +118.2%
- Target range width
- 101.3%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Mineralys Therapeutics?
Mineralys Therapeutics has a verified none consensus. The same dataset has an average price target of $48.50.
How far are Mineralys Therapeutics's low and high targets from the recorded price?
The low target implies +16.9%, while the high target implies +118.2%.
How many analysts are included in Mineralys Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Mineralys Therapeutics's target upside or downside calculated?
The average target of $48.50 is divided by the recorded price of $25.67, then one is subtracted to produce +88.9%. This does not guarantee a future return.
When was Mineralys Therapeutics's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.